Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches
A high number of cancer patients around the world rely on gemcitabine (GEM) for
chemotherapy. During local metastasis of cancers, surgery is beneficial for therapy, but …
chemotherapy. During local metastasis of cancers, surgery is beneficial for therapy, but …
Selectivity through Targeted Protein Degradation (TPD) Miniperspective
A Gopalsamy - Journal of Medicinal Chemistry, 2022 - ACS Publications
Targeted protein degradation has become a reliable tool in the medicinal chemist's toolbox,
as seen with rapid progression of PROTACs (proteolysis targeting chimeras) to clinic …
as seen with rapid progression of PROTACs (proteolysis targeting chimeras) to clinic …
[HTML][HTML] Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …
[HTML][HTML] Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options.
The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti …
The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti …
[HTML][HTML] Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
B Shebl, D Ng, G Lalazar, C Rosemore… - JCI insight, 2022 - ncbi.nlm.nih.gov
Fibrolamellar hepatocellular carcinoma (FLC) is a rare and often lethal liver cancer with no
proven effective systemic therapy. Inhibition of the antiapoptotic protein BCL-XL was found …
proven effective systemic therapy. Inhibition of the antiapoptotic protein BCL-XL was found …
[HTML][HTML] Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
X Peng, Z Hu, L Zeng, M Zhang, C Xu, B Lu… - … Pharmaceutica Sinica B, 2024 - Elsevier
Epigenetic pathways play a critical role in the initiation, progression, and metastasis of
cancer. Over the past few decades, significant progress has been made in the development …
cancer. Over the past few decades, significant progress has been made in the development …
[HTML][HTML] PROTACs in gastrointestinal cancers
Y Chen, Q Yang, J Xu, L Tang, Y Zhang, F Du… - Molecular Therapy …, 2022 - cell.com
Proteolysis targeting chimera (PROTAC) presents a powerful strategy for targeted protein
degradation (TPD). The heterobifunctional PROTAC molecule consists of an E3 ligase …
degradation (TPD). The heterobifunctional PROTAC molecule consists of an E3 ligase …
[HTML][HTML] Laminarin attenuates ROS-mediated cell migration and invasiveness through mitochondrial dysfunction in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously aggressive type of cancer with a
high metastasis rate. It is conventionally treated by surgical resection and neoadjuvant …
high metastasis rate. It is conventionally treated by surgical resection and neoadjuvant …
The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1/NF …
Q Li, J He, S Li, C Tian, J Yang, H Yuan, Y Lu… - Clinical …, 2023 - Elsevier
Cold tumor immune microenvironment (TIME) of pancreatic cancer (PC) with minimal
dendritic cell (DC) and T cell infiltration can result in insufficient immunotherapy and …
dendritic cell (DC) and T cell infiltration can result in insufficient immunotherapy and …
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene
in human pancreatic cancer (∼ 95% of cases). Mutations in KRAS lead to its constitutive …
in human pancreatic cancer (∼ 95% of cases). Mutations in KRAS lead to its constitutive …